GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » U-Neuron Biomedical Inc (ROCO:6973) » Definitions » Retained Earnings

U-Neuron Biomedical (ROCO:6973) Retained Earnings : NT$-84.89 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is U-Neuron Biomedical Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. U-Neuron Biomedical's retained earnings for the quarter that ended in Dec. 2023 was NT$-84.89 Mil.

U-Neuron Biomedical's quarterly retained earnings declined from Dec. 2022 (NT$-43.17 Mil) to Jun. 2023 (NT$-56.07 Mil) and declined from Jun. 2023 (NT$-56.07 Mil) to Dec. 2023 (NT$-84.89 Mil).

U-Neuron Biomedical's annual retained earnings increased from Dec. 2021 (NT$-49.01 Mil) to Dec. 2022 (NT$-43.17 Mil) but then declined from Dec. 2022 (NT$-43.17 Mil) to Dec. 2023 (NT$-84.89 Mil).


U-Neuron Biomedical Retained Earnings Historical Data

The historical data trend for U-Neuron Biomedical's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U-Neuron Biomedical Retained Earnings Chart

U-Neuron Biomedical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Retained Earnings
-37.75 -49.01 -43.17 -84.89

U-Neuron Biomedical Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings -49.01 - -43.17 -56.07 -84.89

U-Neuron Biomedical Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


U-Neuron Biomedical  (ROCO:6973) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


U-Neuron Biomedical (ROCO:6973) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.

U-Neuron Biomedical (ROCO:6973) Headlines

No Headlines